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Abstract
Background
High-grade glioma (HGG) is associated with a limited prognosis. Drug repurposing has
become of increasing interest to improve standard therapy. Statins and NSAIDs inhibit gli-
oma cell growth in vitro and in vivo, but data on statin and NSAID treatment in relation to sur-
vival of patients with HGG are sparse.
Methods
We performed multivariable adjusted Cox-regression analyses among 1,093 patients with
HGG from a regional cancer registry to obtain Hazard Ratios (HRs) with 95% Confidence
Intervals (CIs) for overall survival (OS) and progression-free survival (PFS) according to
treatment with statins or NSAIDs. Data on dose and duration of treatment was mostly lack-
ing in our analysis, therefore we were not able to perform dose-response analyses.
Results
Use of statins was unrelated to OS or PFS of glioma patients. Use of aspirin was associated
with prolonged OS and PFS in patients with WHO grade III, but not WHO grade IV glioma.
Use of other NSAIDs (diclofenac, ibuprofen) or non-NSAID analgesics (paracetamol) was
mostly unrelated to survival of glioma patients. Use of selective COX-2 inhibitors and meta-
mizol was related to inferior patient survival in parts of the analyses.
Conclusions
Use of statins or NSAIDS, including aspirin, was not associated with prolonged OS or PFS
of patients with WHO grade IV glioma in our selected cohort. There was an indication for
improved survival in patients with WHO grade III glioma using aspirin, but further studies are
needed to confirm our first observation.
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Introduction
High-grade gliomas are amongst the deadliest of all cancers [1]. They are classified into World
Health Organization (WHO) grades III and IV, with isocitrate dehydrogenase mutation (IDH-
mut) or IDH wildtype (IDHwt) status. Tumors with presence of an IDH mutation and concur-
rent loss of heterozygosity (LOH) of chromosome arms 1p and 19q are designated as
oligodendrogliomas [2]. Factors influencing survival of patients with HGG include age at diag-
nosis, extent of resection, clinical performance score, MGMT promoter methylation status,
primary therapy and presence of relevant comorbidities [3–5].
Drug repurposing has evolved as a promising field in neurooncology [6]. Several biological
mechanisms exist, through which commonly used medications such as statins or NSAIDS
may influence glioma survival, including targeting of the mevalonate [7–14] or cyclooxygenase
pathways [15–26].
Prior studies are inconclusive with both improved [27], but also unchanged survival of glio-
blastoma patients [28, 29] after statin use. Also, use of NSAIDs and specifically use of selective
COX-2 inhibitors has shown modest effectiveness in some metronomic schemata for glioblas-
toma [30–33], but not in others [34–36].
Based on possible biological mechanisms and in consideration of the low number and
inconclusive results of prior studies investigating survival of patients with HGG after treatment
with statins or NSAIDS, we performed this large retrospective cohort study.
Patients and methods
Data source and study population
We used the population-based clinical cancer registry Regensburg to obtain data from all
patients diagnosed with WHO grade III and IV glioma in the region of Lower Bavaria and
Upper Palatinate according to the ICD-10 and ICD-0 classification between January 1, 1998
and December 31, 2013. The area has about 2.1 million inhabitants, 53 regional hospitals, a
university hospital and over 1,500 practitioners. According to estimates of the German Rob-
ert-Koch Institute (RKI) 98% of all cancer cases are recorded in the cancer registry [37]. The
cancer registry routinely assesses sex, age at diagnosis, year of diagnosis, primary therapy, sta-
tus of molecular markers (MGMT promoter methylation status; IDH mutational status, both
implemented since 2009), date of first progression, date of last follow-up, and date of death.
Vital status of the patient cohort was also verified by death certificates and information from
population registries.
IDH mutational and MGMT promotor methylation status were determined as described
[38].
Patients with other cancers (previously or concurrently, except non-melanoma skin can-
cer), patients with missing follow-up data, and patients younger than 18 years were excluded.
The study was performed in accordance with the Declaration of Helsinki (data collection and
analysis was anonymous), and was approved by the Bavarian Law of Cancer Registration.
Exposures
Information on the extent of resection (biopsy, complete resection, partial resection,
unknown), Karnofsky Performance Score (KPS; 100, 80–90, 60–70, 40–50, 10–30, unknown),
body mass index (BMI; <25, 25–29.9, 30–34.9,�35 kg/m2, unknown), comorbidities (includ-
ing hyperlipidemia and cardiac insufficiency), use of co-medications (including statins (yes,
no; namely simvastatin, atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin); NSAIDS:
diclofenac (yes, no), ibuprofen (yes, no), selective COX-2 inhibitors (yes, no; namely celecoxib,
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rofecoxib and etoricoxib); non-NSAID analgesics: metamizol (yes, no), or paracetamol (yes,
no)) was collected by scanning patient discharge letters, which are collected in the cancer regis-
try. If data were lacking in the registry, we additionally sent standardized questionnaires to
general practitioners. We had complete data for all 1,093 patients (among others) on the date
of diagnosis, age at diagnosis, WHO grade, sex, primary therapy and use of medications (yes/
no). For the MGMT-methylation status, Karnofsky Performance Score, extent of resection
and body-mass index we had lacking data as specified in Table 1. The response rate to the
questionnaires was 21%. For about 30% of patients we had information on dose and duration
of used co-medications.
Statistical analysis
We first analysed factors possibly related to glioma survival using Kaplan-Meier estimates. In
our main analysis, we conducted multivariable COX regression with forward selection to
obtain Hazard Ratios (HRs) with 95% Confidence Intervals (CIs) for overall and progression-
free survival of patients with HGG according to treatment with statins, NSAIDs or non-
NSAID analgesics. As potentially confounding variables we included WHO grade of glioma,
sex, age at diagnosis, year of diagnosis, BMI, MGMT promoter methylation status, IDH muta-
tional status, Karnofsky Performance Score, extent of resection and primary therapy. We
included missing values in a separate category in the multivariable regression model. In addi-
tion, we also performed a minimal model only including age, sex and WHO grade of glioma to
prevent bias due to multicollinearity and statistical over-control. Also, medications were inves-
tigated in separate models.
We set the type I error at 5% for all statistical analyses and all tests were two-tailed. Analyses
were performed using SPSS statistical software version 23. We performed subanalyses investi-
gating drug use stratified by WHO grade of glioma, taking into consideration that the analyses
for WHO grade III are mostly underpowered.
Results
We ascertained 1,093 patients with HGG in our database. Of these, slightly less than half
(43.4%) were women. 862 patients were diagnosed as WHO grade IV, 231 patients as WHO
grade III glioma. The mean age of HGG patients was 59 (± 13.8) years.
Patient characteristics for all HGG patients and according to statin use are displayed in
Table 1, according to aspirin use in Table 2 and according to use of diclofenac, ibuprofen,
selective COX-2 inhibitors, metamizol and paracetamol in S1–S5 Tables. Median follow-up
was 7.3 years. Among patients with known dose, duration and indication of aspirin use (22
patients, 31.4% of all HGG patients taking aspirin) 68% of patients were taking aspirin before
the diagnosis of glioma. 91% of patients took aspirin at a dose of 100 mg daily for cardiovascu-
lar diseases as continuous treatment. Among patients with more detailed information on statin
use (17 patients, 13,9% of all patients taking statins), 94.1% of patients took statins as continu-
ous treatment with a median dose of 20 mg/day. 84.6% of patients were taking statins before
the diagnosis of glioma. 50% of patients on statins had a coding for hyperlipidemia, in addition
statins were used for cardiovascular disease.
Limited information on non-aspirin NSAIDs revealed that they were mostly prescribed
non-continuously and after the diagnosis of glioma (first NSAID prescription after glioma
diagnosis in 85% (ibuprofen), 37.5% (diclofenac) or 100% (COX-2 inhibitors, metamizol and
paracetamol).
In Kaplan-Meier survival analyses worse overall survival was observed in patients with
increasing age, WHO grade IV glioma, lower Karnofsky Performance Score, incomplete
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resection or biopsy only, unmethylated MGMT promoter status, absence of IDH mutation and
absence of combined radiochemotherapy.
A diagnosis of hyperlipidemia (HR for OS = 0.96; 95%CI = 0.78–1.18; p-value = 0.686, HR
for PFS = 0.99; 95%CI = 0.81–1.21; p-value = 0.922), cardiac insufficiency (HR for OS = 1.27;
95%CI = 0.88–1.83; p-value = 0.201, HR for PFS = 1.32; 95%CI = 0.92–1.89; p-value = 0.127)
Table 1. Baseline characteristics according to statin use.
Statin use
Yes
(122, 11.2%)
No
(971, 88.8%)
Total
(1,093, 100%)
count % count % count %
Sex Male 66 54.1% 553 57.0% 619 56.6%
Female 56 45.9% 418 43.0% 474 43.4%
Age at diagnosis < 50 15 12.3% 268 28.6% 283 26.2%
50–59 30 24.6% 230 23.7% 260 23.8%
60–69 39 32.0% 261 26.9% 300 27.4%
> 70 38 31.1% 212 21.8% 250 22.9%
Year of diagnosis 1998–2001 14 11.5% 165 17.0% 179 16.4%
2002–2005 22 18.0% 271 27.9% 293 26.8%
2006–2009 20 16.4% 208 21.4% 228 20.9%
2010–2013 66 54.1% 327 33.7% 393 36.0%
WHO grade III 16 13.1% 215 22.1% 231 21.1%
IV 106 86.9% 756 77.9% 862 78.9%
MGMT-Promotor-Methylation Methylation 28 23.0% 112 11.5% 140 12.8%
Wildtyp 21 17.2% 124 12.8% 145 13.3%
ns 73 59.8% 735 75.7% 808 73.9%
IDH1 Mutation 5 4.1% 49 5.0% 54 4.9%
Wild type 32 26.2% 146 15.0% 178 16.3%
ns 85 69.7% 776 79.9% 861 78.8%
Karnofsky-Performance Score (class. ECOG) 100 ECOG 0 12 9.8% 128 13.2% 140 12.8%
80–90 ECOG 1 41 33.6% 260 26.8% 301 27.5%
60–70 ECOG 2 31 25.4% 132 13.6% 163 14.9%
< 50 ECOG 3, 4 12 9.8% 68 7.0% 80 7.3%
ns 26 21.3% 383 39.4% 409 37.4%
Primary therapy OP+Rad+Chemo 62 50.8% 429 44.2% 491 44.9%
OP+Rad 12 9.8% 154 15.9% 166 15.2%
OP 11 9.0% 91 9.4% 102 9.3%
Rad+Chemo 15 12.3% 80 8.2% 95 8.7%
supportive/others 22 18.1% 217 22.4% 239 22.0%
Extent of resection complete 3 2.5% 36 3.7% 39 3.6%
incomplete 26 21.3% 118 12.2% 144 13.2%
biopsy 19 15.6% 35 3.6% 54 4.9%
ns 74 60.7% 782 80.5% 856 78.3%
BMI < 25.0 18 14.8% 173 17.8% 191 17.5%
25.0–29.9 32 26.2% 158 16.3% 190 17.4%
30+ 25 20.5% 91 9.4% 116 10.6%
ns 47 38.5% 549 56.5% 596 54.5%
Total 122 100.0% 971 100.0% 1093 100.0%
ns = not specified
https://doi.org/10.1371/journal.pone.0207858.t001
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or myocardial infarction (HR for OS = 1.15; 95%CI = 0.73–1.82; p-value = 0.535, HR for
PFS = 0.98; 95%CI = 0.63–1.52; p-value = 0.927) was unrelated to overall or progression-free
survival of patients with HGG. There was a borderline significant positive association between
a history of stroke and survival of patients with HGG (HR for OS = 0.72; 95%CI = 0.52–1.01;
p-value = 0.054, HR for PFS = 0.77; 95%CI = 0.56–1.06; p-value = 0.111).
Use of statins was unrelated to overall or progression-free survival of HGG patients (HR for
OS = 0.95; 95%CI = 0.77–1.18, HR for PFS = 0.91; 95%CI = 0.74–1.13), also when stratified by
WHO grade of glioma (Fig 1). When excluding patients with cardiovascular disease, the results
for statin use and OS remained comparable to those of our main analysis, whereas the results
for PFS were moved towards a non-significant survival-prolonging association of statin use
with progression-free survival (HR for OS = 0.97; 95%CI = 0.78–1.21; HR for PFS = 0.87; 95%
CI = 0.70–1.08). In contrast, use of aspirin was related to significantly better overall and pro-
gression-free survival in patients with WHO grade III (HR for OS = 0.25; 95%CI = 0.10–0.63,
Table 2. Baseline characteristics according to aspirin use.
Aspirin use
Yes
(69, 6.3%)
No
(1,024, 93.7)
Total
(1,093, 100%)
count % count % count %
Sex Male 45 65.2% 574 56.1% 619 56.6%
Female 24 34.8% 450 43.9% 474 43.4%
Age at diagnosis < 60 21 30.4% 522 50.9% 543 49.7%
60–69 15 21.7% 285 27.8% 300 27.4%
> 70 33 47.8% 217 21.2% 250 22.9%
Year of diagnosis 1998–2005 20 29.0% 452 44.2% 472 43.2%
2006–2013 49 71.0% 572 55.9% 621 56.9%
WHO grade III 11 15.9% 220 21.5% 231 21.1%
IV 58 84.1% 804 78.5% 862 78.9%
MGMT-Promotor-Methylation Methylation 16 23.2% 124 12.1% 140 12.8%
Wildtyp 15 21.7% 130 12.7% 145 13.3%
ns 38 55.1% 770 75.2% 808 73.9%
IDH1 Mutation 2 2.9% 52 5.1% 54 4.9%
Wild type 20 29.0% 158 15.4% 178 16.3%
ns 47 68.1% 814 79.5% 861 78.8%
Karnofsky-Performance Score
(class. ECOG)
> 90 ECOG 0,1 30 43.5% 411 40.1% 441 40.3%
< 70 ECOG 2, 3, 4 26 37.7% 217 21.2% 243 22.2%
ns 13 18.8% 396 38.7% 409 37.4%
Primary therapy OP+Rad+Chemo 34 49.3% 457 44.6% 491 44.9%
OP+Rad 13 18.8% 153 14.9% 166 15.2%
supportive/others 22 31.9% 414 40.5% 436 39.9%
Extent of resection complete 4 5.8% 35 3.4% 39 3.6%
incomplete 15 21.7% 129 12.6% 144 13.2%
biopsy 8 11.6% 46 4.5% 54 4.9%
ns 42 60.9% 814 79.5% 856 78.3%
BMI < 25.0 14 20.3% 177 17.3% 191 17.5%
25.0–29.9 16 23.2% 174 17.0% 190 17.4%
30+ 15 21.7% 101 9.9% 116 10.6%
ns 24 34.8% 572 55.9% 596 54.5%
Total 69 100.0% 1024 100.0% 1093 100.0%
https://doi.org/10.1371/journal.pone.0207858.t002
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HR for PFS = 0.31; 95%CI = 0.14–0.72), but not WHO grade IV glioma (HR for OS = 1.02;
95%CI = 0.76–1.58, HR for PFS = 1.04; 95%CI = 0.77–1.39, Fig 1). No relations with overall or
progression-free-survival were noted for use of diclofenac, ibuprofen or paracetamol. In con-
trast, use of selective COX-2 inhibitors was associated with a slightly worse PFS of glioma
patients (HR for PFS = 1.43; 95%CI = 1.05–1.96) and metamizol was associated with a signifi-
cantly worse PFS and borderline significantly worse OS in patients with WHO grade III glioma
(Table 3).
As a minimal model, we repeated analyses on OS of HGG patients only adjusting for age,
gender and WHO grade of glioma with no relevant changes to our main results (HR for aspi-
rin = 0.71; 95%CI = 0.54–0.93; HR for ibuprofen = 1.24; 95%CI = 0.89–1.71; HR for stat-
ins = 0.93; 95%CI = 0.76–1.14; HR for diclofenac = 1.10; 95%CI = 0.67–1.81; HR for COX-2
inhibitors = 0.81; 95%CI = 0.59–1.11).
Fig 1. Kaplan-Meier survival curves for WHO grade III or IV glioma according to use of statins or aspirin.
https://doi.org/10.1371/journal.pone.0207858.g001
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Table 3. Survival of HGG patients in relation to statin, aspirin or non-aspirin-NSAID use.
Variable Number of cases (%) Adjusted HR� (95% CI) p-value
High-grade glioma n = 1,093
Overall Survival
Statins 122 (11.2) 0.95 (0.77–1.18) 0.641
Aspirin 69 (6.3) 0.71 (0.53–0.94) 0.016
Diclofenac 18 (1.6) 1.03 (0.63–1.70) 0.907
Ibuprofen 43 (2.4) 1.30 (0.93–1.83) 0.123
Selective COX-2 inhibitors 50 (4.6) 1.06 (0.75–1.48) 0.752
Metamizol 55 (5.0) 1.00 (0.73–1.38) 0.983
Paracetamol 13 (1.2) 0.83 (0.42–1.63) 0.588
Progression-free Survival
Statins 122 (11.2) 0.91 (0.74–1.13) 0.406
Aspirin 69 (6.3) 0.80 (0.61–1.05) 0.104
Diclofenac 18 (1.6) 1.00 (0.62–1.64) 0.986
Ibuprofen 43 (2.4) 1.26 (0.91–1.74) 0.165
Selective COX-2 inhibitors 50 (4.6) 1.43 (1.05–1.96) 0.026
Metamizol 55 (5.0) 0.99 (0.73–1.36) 0.957
Paracetamol 13 (1.2) 0.95 (0.52–1.76) 0.876
WHO grade III glioma n = 231
Overall Survival
Statins 16 (6.4) 1.16 (0.60–2.26) 0.657
Aspirin 11 (4.8) 0.25 (0.10–0.63) 0.003
Diclofenac 2 (0.9) 1.16 (0.28–4.79) 0.838
Ibuprofen 8 (3.5) 2.14 (0.92–4.95) 0.076
Selective COX-2 inhibitors 11 (4.8) 1.56 (0.67–3.62) 0.304
Metamizol 10 (4.3) 2.08 (0.94–4.58) 0.070
Paracetamol 3 (1.3) 0.82 (0.11–6.02) 0.848
Progression-free Survival
Statins 16 (6.4) 1.06 (0.55–2.06) 0.857
Aspirin 11 (4.8) 0.31 (0.14–0.72) 0.007
Diclofenac 2 (0.9) 0.91 (0.22–3.77) 0.901
Ibuprofen 8 (3.5) 1.86 (0.81–4.28) 0.147
Selective COX-2 inhibitors 11 (4.8) 1.67 (0.78–3.56) 0.185
Metamizol 10 (4.3) 2.46 (1.17–5.17) 0.017
Paracetamol 3 (1.3) 0.85 (0.12–6.23) 0.874
WHO grade IV glioma n = 862
Overall Survival
Statins 44 (5.1) 0.96 (0.76–1.20) 0.714
Aspirin 58 (6.7) 1.02 (0.76–1.58) 0.886
Diclofenac 16 (1.9) 0.98 (0.57–1.67) 0.939
Ibuprofen 35 (4.1) 1.21 (0.83–1.75) 0.323
Selective COX-2 inhibitors 39 (4.5) 0.98 (0.68–1.42) 0.926
Metamizol 45 (5.2) 0.92 (0.65–1.30) 0.628
Paracetamol 10 (1.2) 0.83 (0.40–1.69) 0.602
Progression-free Survival
Statins 44 (5.1) 0.91 (0.72–1.14) 0.396
Aspirin 58 (6.7) 1.04 (0.77–1.39) 0.805
Diclofenac 16 (1.9) 1.03 (0.61–1.74) 0.911
(Continued)
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Discussion
In this large retrospective cohort study, we observed that aspirin use was related to significantly
improved overall and progression-free survival of patients with WHO grade III glioma,
although the analyses are likely underpowered. In contrast, no significant relations were noted
for use of aspirin in patients with statins, non-aspirin NSAIDs, non-NSAID analgesics and
aspirin in patients with WHO grade IV glioma.
Statin use has been found to be related to reduced cancer-related mortality for a variety of
cancers [39], but data on brain cancer and specifically on glioma is sparse. In experimental
studies, statins were found to inhibit cell proliferation and migration and to induce apoptosis
[8, 10, 12–14, 40–43]. Molecular mechanisms include inhibition of the mevalonate metabolism
with downstream modulation of the Ras–Raf–MEK–ERK signaling pathway [7] or Akt signal-
ing [12]. In line with those findings, one study based on 339 glioblastoma patients from the
Danish Cancer registry found a reduced HR of death among patients with prediagnostic statin
use (HR = 0.79; 95% CI: 0.63–1.00) [27]. However, a large Danish study of 5,245 patients
reported no significant association with death from brain cancer among statin users
(HR = 0.95; 95%CI = 0.81–1.12) [39]. In a pooled analysis of randomized clinical trials, includ-
ing 810 patients, there was no association between statin use and survival of patients with pri-
mary glioblastoma [29]. Further, in a study performed in Texas, preoperative statin use was
not associated with improved survival among 284 patients with glioblastoma (HR for
PFS = 0.94, 95% CI = 0.70–1.26) [28]. There have been some recent recommendations in statin
epidemiology literature that some analyses (meta-analyses) should seriously consider exclud-
ing patients with cardiovascular diseases as a best practice [44]. We therefore performed an
additional analysis excluding patients with stroke, cardiac insufficiency or a history of myocar-
dial infarction what did not change our results for OS, but led to a borderline survival-prolong-
ing association of statin use and PFS in patients with HGG.
Our study differs from previous studies in that we included the by far largest number of
patients with high-grade glioma (1,093 patients) and also performed analyses specifically for
WHO grade III gliomas. In addition, our study included statistical adjustments for molecular
marker status as well as primary therapy, KPS, BMI and extent of resection, factors that are
well known to influence survival of patients with HGG.
Non-steroidal inflammatory drugs act by inhibition of cyclooxygenase (COX-1 or 2). High
expression of COX-2 has been linked to poor survival of glioma patients in multivariate
adjusted analyses [45]. Inhibition of prostanoid synthesis by NSAIDs leads to a blockage of
immunosuppressive lymphoid and myeloid cells within the HGG tumor microenvironment
[46, 47]. Inhibition of COX-2 has therefore prompted interest as possible adjuvant treatment
for glioma and was implemented in several metronomic schemata for the treatment of glioma,
with modest positive effects in some studies [30–33], but not in others [34–36] mainly
Table 3. (Continued)
Variable Number of cases (%) Adjusted HR� (95% CI) p-value
Ibuprofen 35 (4.1) 1.28 (0.91–1.82) 0.162
Selective COX-2 inhibitors 39 (4.5) 1.31 (0.93–1.86) 0.123
Metamizol 45 (5.2) 0.85 (0.61–1.20) 0.360
Paracetamol 10 (1.2) 0.95 (0.50–1.81) 0.877
� Model adjusted for age at diagnosis, sex, year of diagnosis, WHO grade (only in complete study), BMI, Karnofsky
Performance Score, Extent of resection, MGMT promoter methylation status, IDH mutation status, primary therapy
https://doi.org/10.1371/journal.pone.0207858.t003
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investigating selective COX-2 inhibitors. In studies evaluating the risk of glioma among
NSAID users, several studies reported an inverse association between NSAID use and glioma
risk [48, 49], but others reported null associations or non-significant inverse associations
between use of aspirin or non-aspirin NSAIDs and glioma risk [50, 51]. Interestingly, one
study stratified according to type of NSAID and noted that only aspirin use was significantly
associated with reduced glioma risk [52] and another study showed overall null results overall
but found a suggestive reduction in glioma risk only in patients with long-term use of aspirin
(OR = 0.80; 95%CI = 0.53–1.21) [53]. Aspirin is the only NSAID that leads to an irreversible
inhibition of cyclooxygenases leading to a longer half-life [54].
Survival of glioma patients after use of aspirin or non-aspirin NSAIDs, except for selective
COX-2 inhibitors, has not much been evaluated. One pooled analysis of randomized clinical
trials explored the effect of daily aspirin intake on long-term risk of death due to cancer and
found a significantly reduced risk of death among brain cancer patients using daily aspirin for
at least 5 years (HR = 0.31; 95% CI, 0.11–0.89) [55]. In another pooled analysis, including
1,273 patients with primary glioblastoma, anticoagulant use and anti-platelet agent use was
explored in relation to patient survival and no significant associations were found [56].
In our analysis, use of aspirin but not use of other NSAIDs was associated with better over-
all survival in patients with WHO grade III glioma, but not in the larger group of patients with
WHO grade IV glioma. Given the absence of relations between use of other NSAIDs and gli-
oma survival, an additional COX-independent mechanism of aspirin appears likely. Patients
with malignancies, including gliomas, harbour an increased risk of venous or arterial embo-
lisms, such as deep vein thrombosis, pulmonary embolism or stroke (reviewed in [57] and
[58]). Use of aspirin has little effect on venous thromboembolism [59], but as platelet aggrega-
tion inhibitor, it reduces the risk of arterial embolism, such as stroke. Secondary prevention of
stroke is mostly performed with aspirin and statins [60] and use of aspirin may therefore
reduce the risk of stroke among patients with glioma.
In addition to COX-dependent factors or possible prevention of arterial embolisms, aspirin
might influence glioma survival by targeting platelets. Platelets are known to exert significant
pro-metastatic and proinvasive properties on human cancers, for example by secreting impor-
tant growth factors, such as transforming growth factor beta, vascular endothelial growth fac-
tor or platelet derived growth factor, thereby influencing the local host immune system,
angiogenesis, proliferation and migration of tumor cells (reviewed in [61]) Use of aspirin as
antiplatelet and anti-invasive agent has been evaluated in breast cancer, colorectal cancer and
head and neck cancer with mostly positive [62–66], but also null results [67, 68], but so far
there is few data on glioma. Interestingly, one study linked preoperative thrombocytosis to sig-
nificantly shortened survival in glioma patients [69].
Reasons, why patients with WHO grade III gliomas have a strong survival benefit after
treatment with aspirin whereas patients with WHO grade IV gliomas have not, are speculative.
Potentially, patients with WHO grade III gliomas have a longer duration of aspirin use due to
a higher life expectancy as compared to patients with WHO grade IV gliomas. However,
results for WHO grade III glioma must be interpreted cautiously, since the analysis is likely
underpowered.
Our study has several limitations mainly including the retrospective nature of the registry,
frequently lacking data on duration and dose of treatment and low sample size in subgroups
which may have led to false positive results. Except for low-dose aspirin, which was used by the
broad majority of our aspirin patients, NSAIDs are often prescribed on demand and not on a
regular basis, which may have caused us to underestimate NSAID use in our patient popula-
tion, limiting our ability to detect potential associations. Confounding by indication may rep-
resent a major source of bias in our retrospective study. Patients who received aspirin may
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differ from patients who did not receive aspirin due to unknown factors of the underlying dis-
eases rather than the medication itself. For example, headaches due to increased intracranial
pressure as a sign of progressive glioma may have led to increased use of certain NSAIDs,
thereby creating a spurious positive association with glioma for medications such as diclofenac
[24–26], COX-2 inhibitors, metamizol, paracetamol or ibuprofen. This is supported by the
fact, that non-aspirin NSAIDs were mostly prescribed after the diagnosis of glioma. We did
however adjust our analysis for the clinical performance score, which should reduce bias due
to severity of glioma symptoms, but was assessed at initial glioma diagnosis. We had large
numbers of unknowns for some covariates, such as molecular markers or the extent of resec-
tion. However, there is no reason to assume that patients with favourable molecular markers
or complete resection were more likely to receive statins or NSAIDS. We were not able to per-
form dose-response analyses because we frequently lacked information on the start date of the
specific medication before glioma diagnosis. However, duration of drug use before glioma
diagnosis may not be relevant for glioma survival. We were not able to stratify our analysis by
steroid use, which may also influence glioma survival [70–72] and we were not able to take
statin intolerance into account, which may influence duration of statin treatment.
Our study also has several notable strengths. Our full dataset has a considerable sample size
and it contains information on important prognostic factors that were accounted for in our
multivariate analyses. This is the first study to evaluate statins and specifically aspirin and non-
aspirin NSAIDs in relation to glioma survival stratified by WHO grade. Our study is not prone
to recall bias because the data regarding medications and diagnoses were collected based on
hospital discharge letters and clinical notes from general practitioners collected in the cancer
registry. Lastly, identification of high-grade glioma patients is likely not influenced by selection
bias because patients were identified using a pre-existing database in our cancer registry.
In summary, we did not observe an association between use of aspirin and survival of
patients with WHO grade IV glioma, but we found an indication for better survival of patients
with WHO grade III glioma after use of aspirin. Further observational studies should be per-
formed including higher sample sizes and more complete information on molecular marker
status and intensity of treatment to validate our first results.
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